Search clinical trials for: BGB-3111 and Drug Cocktail

Total 254029 results

BeiGene

Completed

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males

Healthy Volunteers

United States
Hvidovre University Hospital
University of Copenhagen; Danish Diabetes Academy

Completed

The Late Effects of Ethanol Intake on the Glucose Response to Subcutaneous Glucagon in Type 1 Diabetes (ALCO1)

Hypoglycemia | Diabetes Mellitus, Type 1

Denmark
BeiGene

Completed

A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects

Healthy Subjects

United States
BeiGene

Completed

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Lymphoma | Leukemia

China, Australia
German CLL Study Group

Active, not recruiting

Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation (CLL-RT1)

Richter Transformation

Denmark, Germany, Austria
BeiGene

Recruiting

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Advanced Solid Tumor | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma

Australia, China
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma
BeiGene

Completed

Study to Evaluate the Effect of Food on the Pharmacokinetics of a BGB-3111 in Healthy Subjects

Healthy Volunteers

Australia
BeiGene

Completed

A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma

B-cell Lymphoma

China
BeiGene

Recruiting

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

B-cell Malignancies

China, Italy, United States, Spain, United Kingdom, Poland, Czechia, Netherlands, Greece, France, Sweden, Korea, Republic of, Turkey
BeiGene

Completed

Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants

Healthy Volunteers

United States
BeiGene

Completed

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma (MAGNOLIA)

Marginal Zone Lymphoma | MZL

China, Australia, Italy, France, New Zealand, Czechia, United Kingdom, United States, Korea, Republic of
BeiGene

Completed

Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy Adults

Healthy Volunteers

United States
BeiGene

Active, not recruiting

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

Mature B-cell Malignancies

Japan
BeiGene

Completed

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Refractory Mantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma

China
BeiGene

Recruiting

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

Relapsed Diffuse Large B-cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

China
BeiGene

Completed

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

Waldenström's Macroglobulinemia (WM)

China
BeiGene

Recruiting

Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies

Mature B-Cell Malignancies

United States, Italy, Australia, New Zealand, Spain, Germany, United Kingdom
Peking University People's Hospital

Recruiting

Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma

CNS Lymphoma

China
BeiGene

Completed

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

B-cell Malignancies

United States, Korea, Republic of, Australia, New Zealand, United Kingdom, Italy
BeiGene

Completed

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Relapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic Lymphoma

China
BeiGene

Completed

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

Diffuse Large B-cell Lymphoma

China
BeiGene

Completed

Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants

COVID-19 | COVID-19 Pulmonary Complications

United States
BeiGene

Recruiting

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

CLL

Australia, United States, New Zealand, Korea, Republic of, Canada, Puerto Rico
BeiGene

Completed

A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) (ASPEN)

Waldenström's Macroglobulinemia

United States, Spain, Australia, France, United Kingdom, Germany, Netherlands, Czechia, Italy, Poland, Belgium, Greece, Sweden
BeiGene

Completed

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

B-cell Lymphoid Malignancies

Australia, Korea, Republic of, United States
BeiGene

No longer available

A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies

Waldenström Macroglobulinemia

United States
Phagelux Inc.

Not yet recruiting

Phage Therapy for the Prevention and Treatment of Wound Infections in Burned Patients

Wound Infection
BeiGene

Recruiting

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
BeiGene

Active, not recruiting

Zanubrutinib in Participants With Active Proliferative Lupus Nephritis

Lupus Nephritis

China
University Hospital Tuebingen

Completed

Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC)

COVID-19 Vaccine

Germany
BeiGene

Recruiting

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia

United States, Puerto Rico
Deerland Enzymes

Recruiting

Clinical Study to Evaluate the Safety and Efficacy of New Probiotic Strains in Health Adults

Safety | Gastrointestinal Health | Respiratory Health

Slovenia
BeiGene

Completed

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia (ALPINE)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Poland
British Columbia Cancer Agency
Canadian Cancer Society (CCS); SignalChem Lifesciences Corporation

Recruiting

A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX (SLC-0111-17-01)

Metastatic Pancreatic Ductal Adenocarcinoma

Canada
Queen Savang Vadhana Memorial Hospital, Thailand

Recruiting

RCT - Epidural Anesthetic Cocktail Following Endoscopic Lumbar Discectomy

Lumbar Disc Herniation

Thailand
Nestlé

Terminated

Antibacterial Treatment Against Diarrhea in Oral Rehydration Solution

Diarrhea

Bangladesh
BeiGene

Completed

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Marginal Zone Lymphoma

China
University Hospital, Basel, Switzerland

Completed

In Vivo Determination of Cytochrome P450 Activities in Patients With Liver Cirrhosis (CombiCapsLC)

Liver Cirrhosis

Switzerland
Mackay Memorial Hospital

Unknown

Impaired Immunity in Patients With Cancer: Influence of Cancer Stage, Chemotherapy, and Cytomegalovirus Infection

Neoplasms

Taiwan
BeiGene

Completed

The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males

Healthy | Male

United States
Novo Nordisk A/S

Completed

Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People

Obesity | Overweight | Healthy Volunteers

United States
BeiGene

Terminated

Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors

Advanced Solid Tumors

Australia, Spain, New Zealand
BeiGene

Recruiting

A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy

Primary Membranous Nephropathy

China, United Kingdom, United States
Blade Therapeutics

Completed

Drug-Drug Interaction (DDI) Study in Healthy Volunteers

Drug Drug Interaction

Australia
BeiGene

Active, not recruiting

A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma (ROSEWOOD)

Relapsed/Refractory Follicular Non-Hodgkin Lymphoma

Korea, Republic of, New Zealand, United States, China, Taiwan, Spain, Italy, Australia, Canada, United Kingdom, Belarus, Bulgaria, Czechia, France, Germany, Poland, Russian Federation
Taipei Medical University Shuang Ho Hospital
Taipei Medical University; Delta Electronics

Unknown

Investigation of the Optimal Cocktailed Probiotics for Decolonization of Vancomycin-resistant Enterococci in Human Gut

Probiotics | Vancomycin-Resistant Enterococci

Taiwan
National Center for Complementary and Integrative...

Completed

Identification of the Cranberry Juice Compounds That Prevent Urinary Tract Infections

Urinary Tract Infections

United States
BeiGene
Myriad Genetic Laboratories, Inc.

Completed

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Solid Tumors

United States, Spain, United Kingdom, France, Australia, New Zealand
BeiGene

Recruiting

A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors

Solid Tumor | Advanced Solid Tumor | Metastatic Solid Tumor

United States, France, Australia

3

Subscribe